Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13239764 | 0.87 | MAPT (0.47) | GAAMAPTLMNAKDM4EHTT | |
| SCHEMBL4652078 | 0.87 | MAPT (0.46) | GAAMAPTLMNAKDM4EHTT | |
| SCHEMBL3853309 | 0.86 | MAPT (0.45) | GAAMAPTLMNAKDM4EHTT | |
| SCHEMBL13327274 | 0.85 | POLB (0.52) | GAAMAPTLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL22397770 | 0.85 | POLB (0.52) | GAAMAPTLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL7138685 | 0.84 | MAPT (0.65) | MAPTLMNAHTTALDH1A1SMN1; SMN2 | |
| SCHEMBL25330425 | 0.82 | POLB (0.50) | GAAMAPTLMNAALDH1A1POLB | |
| SCHEMBL13327271 | 0.82 | POLB (0.50) | GAAMAPTLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL3219970 | 0.80 | FABP5 (0.49) | MAPTLMNAALDH1A1SMN1; SMN2POLB | |
| SCHEMBL8222797 | 0.80 | TSHR (0.50) | GAALMNAALDH1A1SMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070072851-A1 | Pyrazolopyridine and pyrazolopyrimidine compounds | AMGEN INC. (US) | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072851-A1 | Pyrazolopyridine and pyrazolopyrimidine compounds | LCK, MAP4K5, TPMT | GAA 1836/4885MAPT 264/4885LMNA 4266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.